Simple dihydrosphyngosine analogues with potent activity against MDR-Mycobacterium tuberculosis

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 19, 2009, Pages 5764-5768

  del Olmo, Esther ^a   Molina Salinas, Gloria María ^b   Escarcena, Ricardo ^a   Alves, Mario ^a   López Pérez, José L ^a   Hernandez Pando, Rogelio ^c   Said Fernández, Salvador ^b   Feliciano, Arturo San ^a  

^a CIETUS   (Spain)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Aminoalcohols; Diamines; Dihydrosphingosine; Ethambutol; H37Rv strain; MDR strain; Mycobactericidal; Mycobacterium tuberculosis

Indexed keywords

DIAMINE DERIVATIVE; ETHAMBUTOL; ETHER DERIVATIVE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; SPHINGANINE;

ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SPHINGOSINE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

MYCOBACTERIUM TUBERCULOSIS;

EID: 69949083585     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.147     Document Type: Article

References (35)

1. http://www.who.int/tb/publications/global_report/2009/en/index.html
2. Andersen P., Doherty T.M., Pai M., and Weldingh K. Trends Mol. Med. 13 (2007) 175
3. http://www.who.int/features/factfiles/tb_facts/en/index1.html
4. WHO report 2009. Global Tuberculosis Control: Epidemiology, Strategy, Financing, Geneva, p 10.
5. http://www.who.int/tb/challenges/mdr/faqs/en/index.html
6. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U., Zeller K., Andrews J., and Friedland G. Lancet 368 (2006) 1575
7. http://www.who.int/tb/challenges/xdr/en/index.html
8. Ahirrao P. Mini-Rev. Med. Chem. 8 (2008) 144
9. Minnikin D.E., Kremer L., Dover L.G., and Besra G.S. Chem. Biol. 9 (2002) 545
10. Lynch K.R., and Macdonald T.L. Biochem. Biophys. Acta 1781 (2008) 508
11. Russell D.G. Nat. Cell Biol. 5 (2003) 776
12. Anes E., Kühnel M.P., Bos E., Moniz-Pereira J., Haberman A., and Griffiths G. Nat. Cell Biol. 5 (2003) 793
13. Takayama K., and Kilburn K.O. Antimicrob. Agents Chemother. 33 (1989) 1493
14. Bhowruth V., Alderwick L.J., Brown A.K., Bhatt A., and Besra G.S. Biochem. Soc. Trans. 36 (2008) 555
15. Cole A., May P.M., and Williams D.R. Agents Actions. 11 (1981) 296
16. Solecki T.J., Aviv A., and Bogden J.D. Toxicology 31 (1984) 207
17. King A.B., and Schwartz R. J. Nutri. 117 (1987) 704
18. Lucas R., Ubeda A., Paya M., Alves M., Olmo E., Lopez J.L., and San Feliciano A. Bioorg. Med. Chem Lett. 10 (2000) 285
19. Olmo E., Alves M., Lopez J.L., Inchaustti A., Yaluff G., Rojas de Arias A., and San Feliciano A. Bioorg. Med. Chem Lett. 12 (2002) 659
20. Olmo E., Macho M., Alves M., Lopez J.L., Banaua F., Muñoz E., and San Feliciano A. Bioorg. Med. Chem Lett. 12 (2002) 2621
21. Lucas R., Alves M., Olmo E., San Feliciano A., and Paya M. Biochem. Pharmacol. 65 (2003) 1539
22. Lucas R., Villamon E., Paya M., Alves M., Olmo E., Gozalbo D., and Gil M.L. FEMS Immunol. Med. Chem. 40 (2004) 239
23. Rangel J., Estrada I., Garcia M.I., Aguilar D., Marquez R., and Hernández-Pando R. Immunology 106 (2002) 257
24. Rook G.A.W., Lowrie D.B., and Hernández-Pando R. J. Infect. Dis. 196 (2007) 191
25. Olmo E., Plaza A., Muro A., Martínez-Fernández A.R., Nogal-Ruiz J.J., López-Pérez J.L., and San Feliciano A. Bioorg. Med. Chem. Lett. 16 (2006) 6091
26. Uribe N., Siles-Lucas M., López-Abán J., Esteban A., Suarez L., Martínez-Fernandez A.R., Olmo E.del., and Muro A. Vaccine 25 (2007) 4533
27. Siles-Lucas M., Uribe N., López-Abán J., Vicente B., Orfao A., Nogal-Ruiz J.J., San Feliciano A., and Muro A. Vaccine 25 (2007) 7217
28. López-Abán J., Nogal-Ruiz J.J., Vicente B., Diez-Baños P., Hillyer G.V., Martínez-Fernández A.R., San Feliciano A., and Muro A. Vet. Parasitol. 153 (2008) 176
29. 25 This strain was resistant to the critical antimicrobial concentration of S, I, R, E and P. Other MDR-MTB strains (Table 2) were characterised similarly.
30. 2 permeable sealed bag), 32 μL of freshly prepared 20:12 mixture Alamar Blue plus 10% Tween-80 (v/v) were added to each well. The plates were re-incubated at 37 °C for 24 h. Pink and blue colours indicated mycobacterial growth or its absence, respectively. The MIC value for a tested compound was assigned to that of the first blue well. Destruction of mycobacteria in the first blue well was confirmed microscopically.
31. Molina-Salinas G.M., Ramos-Guerra M.C., Vargas-Villarreal J., Mata-Cárdenas B.D., Becerril-Montes P., and Said-Fernández S. Arch. Med. Res. 37 (2006) 45
32. 2: C, 72.76; H, 12.70; N, 6.79. Found: C, 72.75; H, 12.68; N, 6.73.
33. Rattan A., Kalia A., and Ahmad N. Emerg. Infect. Dis. 4 (1998) 195
34. Whelen A.C., Felmlee T.A., Hunt J.M., Williams D.L., Roberts G.D., Stockman L., and Persing D.H. J Clin. Microbiol. 33 (1995) 556
35. Siddiqi, S. BACTEC-460 TB System, product and procedure manual. Revision E. 1996. Becton Dickinson Mycrobioly Systems, Sparks, MD.